Integrating Experimental and Data Science Capabilities

Under the terms of the agreement, Odyssey Therapeutics will utilize Evotec’s proprietary drug discovery platform. This platform combines extensive compound libraries and advanced screening capabilities with machine learning-driven analysis and AI-enabled data science technologies. By leveraging high-throughput experimentation alongside data-driven insights, the companies seek to discover and validate differentiated small molecule drug candidates across multiple high-value targets.

The approach is designed to accelerate the identification of validated hit series and support the swift progression of early-stage research programs into potential therapeutic options.

Strategic Alignment and Discovery Goals

Speaking on the strategic approach, Evotec Chief Scientific Officer Cord Dohrmann, PhD, noted that drug discovery increasingly relies on uniting deep disease biology with modern experimental platforms.

“This collaboration with Odyssey illustrates well Evotec’s strategy in applying integrated discovery platform technologies to complex disease areas,” Dohrmann stated. “We aim to generate differentiated, validated starting points for Odyssey to develop into new therapies for autoimmune and inflammatory diseases.”

Through this partnership for autoimmune and inflammatory diseases, both organizations aim to combine complementary technological and scientific capabilities to enhance early-stage drug development. The effort focuses on delivering scalable starting points aimed at advancing future inflammatory disease treatments.

Structure of the Financial Agreement

While specific financial figures were not disclosed, the agreement establishes that Evotec is eligible for milestone payments tied to performance. These payments are contingent upon the successful delivery of validated hit series for each specified target, structuring the collaboration to link value creation directly to drug discovery achievements through their shared drug discovery platform.

Expanding Technological Integration Across Scientific Teams

Under the new arrangement, BMS scientific teams will scale the use of Schrödinger technologies, including the Bunsen AI co-scientist platform and RetroSynth, an AI-driven synthesis planning system. The collaboration aims to enable researchers to explore chemical space more extensively, prioritize molecular candidates with increased confidence, and support decision-making in the early stages of drug discovery.

Bunsen is designed as an agentic AI co-scientist tailored to perform complex workflows in molecular design and computational research. It carries out Schrödinger’s physics-based computational methods, conducts planning and interpretation tasks, and integrates with other research technologies. Complementing this, RetroSynth enables high-throughput evaluation of chemical synthesis planning pathways to evaluate candidate structures efficiently.

Statements from Leadership

Robert Abel, chief scientific officer of the Schrödinger platform, said, “BMS is a long-standing customer and collaborator, and they have been an industry leader in integrating computation into drug discovery. We are thrilled they are deploying Bunsen at a large scale. Adopting Bunsen and our computational platform at scale will empower a broader group of scientists to embrace a predict-first computational approach.”

Stephen Johnson, vice president of computational sciences at BMS, said, “Over the past several years, AI has become a key enabler for our scientists, allowing them to scale their creativity and scientific expertise across our research organisation. Bunsen is another capability we are adding to that toolkit, one that allows our scientists to think differently about how physics-based tools can be used to navigate molecular design space and accelerate the discovery of innovative medicines for patients.”

Core Capabilities and Recent Computational Developments

Schrödinger’s software platform combines artificial intelligence with physics-based simulation to support hypothesis evaluation and synthetic feasibility in molecular research. The organization’s computational solutions are licensed by entities across the global pharmaceutical, biotechnology, industrial, and academic sectors.

Metabolic diseases, including obesity and diabetes, have reached pandemic proportions, straining healthcare systems and diminishing the quality of life for a significant portion of the global population. The physiological role of GLP-1 is multifaceted; it stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying, all while signaling the brain to increase feelings of satiety. Pharma Advancement notes that by mimicking this natural hormone, GLP-1 drugs have demonstrated remarkable efficacy in reducing blood sugar levels and inducing substantial weight loss. The transition to oral formulations is not merely a matter of convenience; it is a fundamental pharmaceutical innovation that addresses the deep-seated psychological and logistical hurdles associated with chronic injectable therapies.

The Challenge of Oral Peptide Delivery

To understand the significance of oral GLP-1 drugs, one must appreciate the immense scientific challenge of delivering peptides via the gastrointestinal tract. Peptides are essentially chains of amino acids, and the human stomach is a highly hostile environment designed specifically to break these chains down. Acidic gastric juices and proteolytic enzymes typically destroy peptides long before they can reach the bloodstream. For a GLP-1 agonist to be effective in pill form, it must survive this digestive gauntlet and penetrate the intestinal lining with enough bioavailability to achieve a therapeutic effect.

The solution to this problem has come in the form of innovative chemical carriers and novel molecular engineering. One of the most notable successes in this field involves the use of SNAC (sodium salcaprozate), a small-molecule absorption enhancer that temporarily raises the local pH in the micro-environment of the stomach. This localized pH shift prevents the acidic degradation of the peptide, allowing the medication to be absorbed directly through the gastric mucosa. While the bioavailability of oral peptides remains significantly lower than that of their injectable counterparts, the ability to deliver a consistent, daily supra-physiological dose via a tablet has opened a new chapter in metabolic disease therapy.

Furthermore, ongoing drug development is now branching into two distinct paths. The first involves optimizing these peptide-carrier combinations to improve absorption and reduce the variability caused by food intake. The second path is the development of non-peptide, small-molecule GLP-1 receptor agonists. Unlike peptides, these small molecules are inherently stable in the digestive system and do not require specialized carriers for absorption. These next-gen oral GLP-1 drugs could potentially offer higher bioavailability and simpler manufacturing processes, making them even more attractive for large-scale global distribution. The focus is not just on making a pill, but on making a pill that is as robust and reliable as any other standard medication in a patient’s cabinet.

Impact on Patient Compliance and Obesity Treatment

The shift toward oral GLP-1 drugs is expected to have a profound impact on patient compliance and the overall trajectory of obesity treatment. In the context of chronic disease, adherence is the single most important factor in achieving long-term health outcomes. Many patients suffer from needle phobia or find the logistics of storing and disposing of injectable pens to be cumbersome. By offering a daily pill that can be taken alongside other common medications, healthcare providers can lower the threshold for starting treatment. This is particularly important for obesity, which is often under-treated due to the stigma and the perceived intensity of existing medical interventions.

Furthermore, the oral format allows for more flexible dosing strategies. Injectables are often administered weekly, which can lead to fluctuations in drug levels and potential side effects as the body adjusts to each dose. A daily oral tablet provides a more steady state of the medication in the bloodstream, which may improve tolerability for some patients. As the medical community increasingly recognizes obesity as a chronic, relapsing metabolic disease rather than a failure of willpower, the availability of oral GLP-1 drugs provides a practical and sustainable tool for long-term management. This transition is not just about weight loss; it is about reducing the incidence of co-morbidities like cardiovascular disease, sleep apnea, and fatty liver disease.

Pharmaceutical Innovation and Market Dynamics

The race to dominate the market for oral GLP-1 drugs has spurred unprecedented competition among global pharmaceutical giants. The potential market for these medications is estimated to be in the tens of billions of dollars, reflecting the vast unmet need in metabolic health. Companies are not just competing on delivery methods but also on the potency of the molecules. We are now seeing the development of multi-receptor agonists, often called twincretins or triple G agonists, which target GLP-1 along with other hormones like GIP (glucose-dependent insulinotropic polypeptide) and glucagon.

When these multi-hormone agonists, such as the promising Triple G agonists like Retatrutide, are successfully formulated into oral GLP-1 drugs, the clinical results could be even more dramatic than the successes we see today. The ultimate goal of current drug development is to match, or even exceed, the weight-loss efficacy of bariatric surgery through a simple, once-daily pill. Achieving a 20% to 25% reduction in total body weight via pharmacotherapy would represent a paradigm shift in how we approach metabolic health on a population scale. It would move obesity from the realm of surgical intervention into the realm of primary care management, similar to how statins transformed the treatment of high cholesterol.

However, this wave of pharmaceutical innovation also brings significant challenges related to manufacturing and global supply chains. The production of peptides in the massive quantities required for daily oral dosing is significantly more complex and resource-intensive than the production of once-weekly injectables. A daily oral dose requires a much larger amount of the active pharmaceutical ingredient (API) due to the lower bioavailability. This has led to concerns about peptide shortages and the ability of the industry to scale production to meet the skyrocketing global demand. Ensuring that these life-saving innovations remain affordable, accessible, and equitably distributed is a critical challenge that will require collaboration between the pharmaceutical industry, healthcare providers, and global policymakers.

The Societal and Economic Implications of Metabolic Health

The widespread adoption of oral GLP-1 drugs will likely have ripple effects far beyond the walls of the clinic. Obesity and its related conditions are major drivers of healthcare spending, productivity loss, and disability. By providing a scalable and effective means of managing these conditions, the new generation of GLP-1 therapies could lead to a significant reduction in the global burden of metabolic disease. This could translate into billions of dollars in savings for national health systems and improved economic participation for millions of individuals.

Moreover, the psychological impact of moving away from the willpower myth of weight loss cannot be overstated. By framing obesity as a biological condition that can be treated with a pill, these drugs are helping to dismantle the pervasive stigma that has long surrounded the disease. This cultural shift, combined with the ease of use of oral medications, may encourage more people to seek help earlier in their disease progression. As we look toward the 2030s, the legacy of oral GLP-1 drugs will likely be measured not just in pounds lost or blood sugar lowered, but in the fundamental reorganization of how society values and protects metabolic health.

Future Outlook: Beyond Diabetes and Obesity

Pharma Advancement believes that the potential applications for oral GLP-1 drugs may extend far beyond their current indications for diabetes and obesity. Emerging research suggests that GLP-1 receptors are present in many parts of the body, including the brain, heart, and kidneys. There is significant interest in the potential of these drugs to treat neurodegenerative conditions like Alzheimer’s and Parkinson’s disease, where they may exert neuroprotective effects. Additionally, the anti-inflammatory properties of GLP-1 agonists are being investigated for the treatment of non-alcoholic steatohepatitis (NASH) and chronic kidney disease.

The transition to oral delivery makes these broad applications much more feasible. It is far more practical to prescribe a daily pill for a neurodegenerative condition or a chronic inflammatory disease than it is to require lifelong weekly injections. As our understanding of metabolic health continues to deepen, we may find that metabolic disease therapy becomes a cornerstone of preventative medicine. In this future, oral GLP-1 drugs could be used not just to treat existing illness but to optimize metabolic function and extend the healthy lifespan of the general population. The journey from the lab to the pharmacy shelf is long and arduous, but the progress made in the last decade suggests that the best is yet to come.

Pharma Advancement notes that the evolution of GLP-1 drugs beyond weight loss is driven by a deepening understanding of the GLP-1 receptor’s distribution throughout the human body. While the initial focus was on the pancreas and the brain’s appetite centers, researchers have identified these receptors in the heart, kidneys, liver, and even the central nervous system. This biological map has opened the floodgates for drug development, leading to a surge in clinical trials designed to test the efficacy of these molecules against a spectrum of diseases that, on the surface, seem unrelated to blood sugar or body mass index. In 2026, the medical community is witnessing the fruition of these efforts as regulatory bodies and clinical guidelines expand to include indications that were once considered outside the scope of incretin-based therapies.

The Cardiovascular Renaissance

Perhaps the most significant expansion of GLP-1 drugs beyond weight loss is occurring within the realm of cardiovascular health. For years, the primary goal of heart disease management was the control of cholesterol and blood pressure. However, the results of massive cardiovascular outcomes trials have repositioned GLP-1 drugs as foundational tools for reducing major adverse cardiovascular events (MACE). In 2026, cardiologists are increasingly prescribing these medications not just for their metabolic benefits but for their direct cardioprotective effects.

The mechanism is multifaceted. Beyond the indirect benefits of weight reduction and improved glycemic control, GLP-1 receptor agonists appear to improve endothelial function, reduce systemic inflammation, and even modulate the heart’s utilization of energy. Clinical data has shown a marked decrease in the risk of stroke and myocardial infarction in non-diabetic populations, a finding that has fundamentally altered the standard of care. This transition is particularly evident in the treatment of heart failure with preserved ejection fraction (HFpEF), a condition that long lacked effective pharmacological options. By addressing the systemic inflammation and metabolic dysfunction that often underpin HFpEF, GLP-1 drugs have filled a critical therapeutic void, offering patients a path toward improved exercise capacity and quality of life.

Transforming the Landscape of Chronic Kidney Disease

The intersection of metabolic disease and renal health has historically been a site of significant clinical frustration. Chronic kidney disease (CKD) often progresses silently, frequently leading to dialysis or transplantation. However, 2026 stands as a turning point in nephrology, largely due to the integration of GLP-1 drugs into renal protection protocols. Early results from landmark trials, such as the FLOW study, demonstrated that semaglutide could reduce the risk of kidney disease progression and renal death by nearly a quarter.

This nephroprotection is not merely a byproduct of lowered blood pressure. The presence of GLP-1 receptors in the proximal tubules of the kidney suggests a direct interaction that reduces oxidative stress and fibrosis. For patients with type 2 diabetes and comorbid CKD, these drugs have become a cornerstone of therapy, often used in conjunction with SGLT2 inhibitors to create a dual-pillar approach to kidney preservation. The expansion into non-diabetic CKD is the next frontier, with clinical trials in 2026 actively exploring how pharmaceutical innovation can decouple these renal benefits from the drug’s original glucose-lowering intent.

The Rise of MASH and Liver Health

Metabolic-associated steatohepatitis (MASH), formerly known as NASH, has become one of the leading causes of liver transplantation worldwide. Characterized by fat accumulation, inflammation, and progressive scarring, MASH has historically been treated with lifestyle modification—a recommendation that often proves insufficient for advanced cases. The arrival of next-generation GLP-1 drugs, particularly those that also target glucagon and GIP receptors, has changed the prognosis for millions.

In 2026, the clinical focus has shifted toward dual and triple agonists like survodutide and tirzepatide, which have shown remarkable ability to reduce liver fat content and, in some cases, reverse fibrosis. These advances in drug development are particularly exciting because they address the root cause of the metabolic disease rather than just the symptoms. By optimizing the liver’s metabolic environment, these drugs help prevent the progression to cirrhosis and hepatocellular carcinoma. The pharmaceutical market in 2026 reflects this shift, with MASH emerging as a primary indication that justifies the high cost of these therapies for insurers and healthcare systems.

Navigating the Neuro-Frontier: Parkinson’s and Alzheimer’s

The most debated and high-stakes expansion of GLP-1 drugs involves the central nervous system. The brain-gut axis is no longer a theoretical concept but a clinical target. Researchers have long noted that patients with metabolic dysfunction have a higher risk of neurodegenerative diseases, leading to the hypothesis that GLP-1 drugs might offer neuroprotective benefits. In 2026, the results of this research are presenting a nuanced picture.

While early trials in Alzheimer’s disease, such as the EVOKE series, faced challenges in meeting primary endpoints across broad populations, they have provided invaluable data on how these drugs modulate neuroinflammation. In contrast, the application of GLP-1 receptor agonists in Parkinson’s disease has shown significant promise. Drugs like lixisenatide have demonstrated the potential to slow the progression of motor symptoms by protecting dopaminergic neurons from inflammatory damage. This highlights a shift in drug development toward disease-modifying rather than merely symptom-managing neurology. Even where trials have been mixed, the 2026 perspective is one of refinement—identifying the specific sub-populations and stages of disease where metabolic intervention can most effectively halt cognitive or motor decline.

Sleep Apnea and the Resolution of Obstructive Disorders

The relationship between obesity treatment and obstructive sleep apnea (OSA) is well-documented, but 2026 has seen GLP-1 drugs receive specific clinical indications for this condition. For many patients, OSA is a mechanical issue driven by excess tissue in the airway, but it is also a metabolic issue characterized by systemic inflammation and altered respiratory drive. The SURMOUNT-OSA trials provided the clinical evidence necessary to prove that GLP-1 drugs can reduce the apnea-hypopnea index (AHI) by over 60% in many individuals.

This has profound implications for cardiovascular health, as untreated sleep apnea is a major driver of hypertension and arrhythmias. By addressing OSA through pharmacological means, clinicians in 2026 are able to offer an alternative or an adjunct to CPAP machines, which often suffer from low patient compliance. This represents a holistic approach to metabolic disease, where a single molecule can simultaneously address weight, blood pressure, and sleep architecture.

Addiction and the Dopamine Reward Pathway

One of the more unexpected developments in 2026 is the emerging use of GLP-1 drugs in treating addictive disorders. Anecdotal evidence from early adopters of semaglutide suggested a significant reduction in cravings for alcohol, nicotine, and even impulse shopping. Rigorous clinical trials are now catching up to these observations. By modulating the dopamine reward pathways in the brain’s ventral tegmental area, GLP-1 drugs appear to quiet the noise of addictive impulses.

This indicates a future where drug development for substance use disorders might pivot toward metabolic pathways. While still in the early stages of broad clinical adoption, the potential for GLP-1 drugs beyond weight loss to tackle the opioid crisis or alcohol use disorder is a major topic of discussion at medical congresses in 2026. It underscores the drug’s role as a systemic regulator of human behavior and biology, rather than just a tool for calorie restriction.

The Pharmaceutical Innovation of 2026: Multi-Agonists and Delivery

As clinical indications expand, so too does the technology behind the drugs. The 2026 pharmaceutical market is characterized by a move away from simple GLP-1 mono-therapy toward multi-agonists. These ‘triple G’ molecules—targeting GLP-1, GIP, and glucagon receptors—provide a more potent metabolic signal, allowing for better efficacy in difficult-to-treat conditions like advanced MASH or severe obesity-related heart failure.

Furthermore, the innovation in delivery systems has addressed one of the biggest hurdles to widespread adoption: the needle. Oral formulations and long-acting monthly injectables have become standard, improving patient adherence and expanding the drug’s reach into primary clinical care. This accessibility is crucial as the list of indications grows. A drug that can treat a dozen different chronic conditions is only useful if patients can maintain the regimen over decades.

Ethical and Economic Considerations in a New Era

The rapid expansion of GLP-1 drugs into so many areas of medicine brings significant economic challenges. In 2026, the conversation has moved from should these drugs be used to how can every person in need afford to use them. With indications now spanning heart, kidney, liver, and brain health, the potential patient pool is enormous. This has led to a restructuring of insurance models, where the high upfront cost of the medication is weighed against the massive long-term savings of preventing dialysis, heart transplants, and nursing home care for neurodegenerative conditions.

There is also a human element to this shift. Patients who previously felt stigmatized by the use of weight loss drugs now find themselves taking a metabolic stabilizer that protects their heart and kidneys. This change in framing is essential for patient dignity and for the integration of these therapies into routine clinical care. The professional insight of 2026 recognizes that obesity was never a siloed condition, but a central node in a web of systemic dysfunction.

The landscape of 2026 is defined by a sense of cautious optimism. While the magic pill narrative is always dangerous in medicine, the data supporting the systemic benefits of GLP-1 drugs is increasingly difficult to ignore. From the stabilization of renal function to the reduction of neuroinflammation, these molecules are proving that the human body’s metabolic and inflammatory systems are inextricably linked. Pharma Advancement believes that the role of GLP-1 drugs will likely only continue to grow, cementing their place as one of the most versatile and impactful classes of medication in the history of modern pharmacology.

The current gold standards, Semaglutide and Tirzepatide, have set a high bar. Semaglutide, a selective GLP-1 receptor agonist, proved that significant weight loss was possible through the mimicry of natural satiety hormones. Eli Lilly’s Tirzepatide took this a step further by introducing a dual-agonist approach, targeting both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This combination demonstrated that hitting multiple metabolic pathways could yield weight loss results previously achievable only through bariatric surgery. As the medical community looks toward the horizon, Pharma Advancement notes that the collective focus is shifting. Scientists are no longer just asking how much weight can be lost, but rather how that weight is lost, how easily the medication can be administered, and whether these peptide therapeutics can treat more than just the scale.

The Rise of Triple Agonism and the Promise of Retatrutide

One of the most anticipated breakthroughs in drug development is the move from dual to triple agonism. Retatrutide represents the vanguard of this movement. While Tirzepatide targets two receptors, Retatrutide adds a third: the glucagon receptor. By activating GLP-1, GIP, and glucagon receptors simultaneously, this ‘triple G’ molecule addresses metabolic disease from three distinct angles. The inclusion of glucagon is particularly noteworthy because it increases energy expenditure and targets liver fat directly, while the GLP-1 and GIP components manage appetite and insulin secretion.

Early-phase clinical trials for Retatrutide have shown weight loss percentages that exceed anything seen to date, with some participants losing over 24% of their body weight in less than a year. This level of efficacy suggests that next-generation GLP-1 drugs might soon make the plateau experienced by some patients on Semaglutide a thing of the past. Beyond the sheer numbers, the activation of the glucagon receptor offers specific benefits for patients with metabolic dysfunction-associated steatotic liver disease, formerly known as NASH. By mobilizing fat stores in the liver, these multi-agonists are proving that obesity treatment and diabetes therapy are just the beginning of their systemic utility.

Breaking the Injection Barrier with Oral Formulations

Despite the success of injectable medications, a significant portion of the population remains hesitant to use needles, and the logistics of cold-chain storage and self-injection present barriers to global scale. Consequently, the race for a potent, non-peptide oral alternative is a central pillar of current pharmaceutical innovation. While an oral version of Semaglutide already exists for diabetes therapy, its absorption is highly sensitive to food and water intake, requiring strict fasting protocols that can be difficult for patients to maintain.

The next generation of oral therapies, such as Orforglipron, aims to solve these challenges. Unlike Semaglutide, which is a peptide, Orforglipron is a small-molecule GLP-1 receptor agonist. This chemical structure allows it to be absorbed more easily in the gastrointestinal tract without the stringent requirements of its predecessors. Small molecules are also generally cheaper and easier to manufacture at scale than peptide therapeutics. The shift toward daily pills that do not require refrigeration could democratize access to obesity treatment, making it feasible for primary care physicians to prescribe these medications to a much wider patient base, particularly in regions where the infrastructure for injectable biologics is lacking.

Synergistic Combinations and the Role of Amylin

Another fascinating avenue in the development of next-generation GLP-1 drugs is the combination of GLP-1 with other hormone analogues like Amylin. Amylin is a hormone co-secreted with insulin that signals fullness through a different pathway than GLP-1. Novo Nordisk’s CagriSema, a fixed-dose combination of Cagrilintide (an amylin analogue) and Semaglutide, is currently in late-stage trials. The rationale behind this combination is synergy; by hitting two different satiety signals in the brain, the drug may achieve greater weight loss with lower doses of each individual component, potentially reducing the gastrointestinal side effects that often plague high-dose GLP-1 therapy.

This approach highlights a broader trend in metabolic disease research: the move away from monotherapy and toward poly-pharmacy in a single pen. By layering different mechanisms of action, researchers can fine-tune the metabolic response. For example, while GLP-1 primarily focuses on the brain’s reward and hunger centers, amylin analogues have a profound effect on gastric emptying and the post-prandial glucose response. The result is a more comprehensive metabolic profile that addresses the complex, redundant systems the human body uses to maintain its weight.

Prioritizing Quality of Loss and Muscle Preservation

As the first generation of these drugs reached millions of users, a specific concern emerged among clinicians: the quality of weight loss. When individuals lose weight rapidly, they often lose a significant amount of lean muscle mass along with adipose tissue. This is a particular concern for the elderly or those with sarcopenia, as muscle loss can lead to frailty and metabolic slowing. Next-generation GLP-1 drugs are increasingly being evaluated not just for their ability to reduce fat, but for their ability to preserve muscle.

Innovative trials are now pairing GLP-1 agonists with myostatin inhibitors or activin receptor blockers. Myostatin is a protein that inhibits muscle growth; by blocking it, researchers hope to ensure that the weight lost during treatment comes almost exclusively from fat stores. This evolution marks a shift from a weight-centric model of health to a body composition model. If pharmaceutical innovation can solve the muscle-loss dilemma, these drugs will become much safer and more effective for long-term use across a broader range of age groups, ensuring that patients end up not just thinner, but stronger and more metabolically resilient.

Addressing the Side Effect Profile and Tolerability

While the efficacy of current drugs is undisputed, the real-world persistence—how long patients actually stay on the medication—is often limited by side effects. Nausea, vomiting, and diarrhea are common hurdles that prevent many from reaching an effective dose. The next generation of therapies is being engineered with improved pharmacokinetics to minimize these peaks and valleys in drug concentration.

Some companies are exploring slow-release technologies or long-acting formulations that require only monthly or even quarterly administration. By smoothing out the delivery of the drug, the sudden impact on the gastrointestinal system may be lessened. Furthermore, as we move toward small-molecule orals, the ability to more precisely titrate dosages could allow patients to find their ‘Goldilocks dose’—the amount of drug that provides maximum benefit with minimal discomfort. This focus on the patient experience is a critical component of modern drug development, recognizing that a drug is only effective if the patient is willing and able to take it consistently.

The Expanding Therapeutic Horizon: MASH, Heart Failure, and Beyond

Perhaps the most exciting aspect of next-generation GLP-1 drugs is their potential to treat conditions far removed from diabetes and obesity. We are seeing a broadening of the therapeutic horizon into neurology, cardiology, and hepatology. Recent studies have suggested that GLP-1 receptors in the brain may play a role in neuroinflammation, leading to trials for Alzheimer’s and Parkinson’s diseases. The anti-inflammatory effects of these peptides are also being studied in the context of chronic kidney disease and heart failure with preserved ejection fraction.

In the realm of cardiovascular health, the SELECT trial already showed that Semaglutide reduces the risk of major adverse cardiovascular events by 20% in patients with obesity but without diabetes. The next generation aims to build on this by specifically targeting the mechanisms of atherosclerosis and systemic inflammation. This suggests that in the near future, GLP-1-based therapies might be prescribed as primary preventive measures for heart disease, much like statins are today. The transition from a weight loss drug to a systemic health optimizer is well underway, fundamentally changing how we approach the treatment of chronic, age-related diseases.

Economic and Global Health Implications

The arrival of more diverse and easier-to-manufacture metabolic therapies will inevitably impact the economics of healthcare. Current costs for peptide therapeutics are high, driven by complex manufacturing processes and high demand. However, as more players enter the market with next-generation GLP-1 drugs—including small molecules and biosimilars—the competitive landscape will likely drive prices down. This is essential for addressing the global obesity epidemic, which disproportionately affects lower-income populations and developing nations.

Furthermore, the potential for these drugs to reduce the long-term burden of diabetes-related complications, such as dialysis, amputations, and heart surgery, could result in significant savings for healthcare systems. The focus is shifting toward value-based outcomes, where the cost of the drug is weighed against the massive expense of treating untreated metabolic disease. As pharmaceutical innovation continues to yield more potent and accessible options, the goal of making these life-changing therapies available to the hundreds of millions who need them becomes more realistic.

The progress we have seen with Semaglutide and Tirzepatide is merely the foundation for a much more sophisticated era of metabolic medicine. The next generation of GLP-1 drugs promises not only higher efficacy but also better delivery systems, improved safety profiles, and the ability to preserve vital muscle mass. Pharma Advancement believes that by targeting multiple hormone receptors and expanding into new therapeutic areas like liver and brain health, these treatments are redefining our understanding of chronic disease management. As we move beyond the current landscape, the focus remains on personalizing therapy to the individual, ensuring that the metabolic revolution is as sustainable as it is effective. The shift from treating symptoms to addressing the underlying hormonal drivers of health represents one of the most significant leaps in medical history, signaling a future where metabolic vitality is within reach for a global population.

But theranostics, and the broader boom in imaging-guided and longevity-focused diagnostics, rests on two unglamorous foundations that almost never make the headlines: the chelator chemistry that makes an imaging agent work, and the quality assurance that makes a scanner’s output trustworthy. Get either one wrong and the whole promise collapses. A beautifully designed radioligand is worthless if it can’t hold its payload stably in the body; a perfectly targeted contrast agent tells you nothing if the scanner producing the image hasn’t been calibrated against a known standard. This piece looks at both ends of that chain — the molecule and the machine — and why the industry should care about the parts it tends to overlook.

The Molecule: Chelators Are the Unsung Workhorses

Most modern imaging and theranostic agents share a common architecture: a targeting group that seeks out diseased tissue (such as PSMA for prostate cancer or somatostatin receptors for neuroendocrine tumors), a linker, and a chelator that cages a metal. That metal may be a radioisotope for PET or SPECT — gallium-68, copper-64, zirconium-89 for imaging; lutetium-177 or actinium-225 for therapy — or a paramagnetic ion for MRI contrast. The chelator’s job sounds simple and is anything but. It must grip its metal tightly enough that the isotope doesn’t leak into healthy tissue, while presenting clean, reproducible chemistry that survives conjugation and scale-up.

This is why families of macrocyclic chelators like DOTA and DOTAGA have become foundational infrastructure. Suppliers specializing in high-purity chelator chemistry are helping developers standardize conjugation strategies through better-defined intermediates: PurePEG offers DOTA-based chelators and bifunctional imaging linkers across a range of monodisperse DOTA, DOTAGA, and protected-DOTA scaffolds, operating within an ecosystem that also includes Macrocyclics, CheMatech, and BroadPharm. When these building blocks are supplied as high-purity, well-characterized units, developers can move from concept to conjugate without fighting batch variability at every step. As the same targeting scaffolds get paired with diagnostic and therapeutic metals — the essence of the theranostic model — demand for reliable chelator and linker chemistry only intensifies.

The Machine: An Image Is Only as Good as Its Quality Assurance

Now follow that agent into the imaging suite, and a second, equally decisive foundation comes into view. An MRI, PET/CT, or PET/MRI scanner is a precision instrument that drifts. Gradients, coils, and field homogeneity all shift over time, and without routine calibration the images they produce become unreliable — a serious problem when clinicians are measuring lesion size, tracking change across visits, or quantifying uptake for treatment decisions.

That is the entire purpose of the quality-assurance layer around every serious imaging program: standardized phantoms scanned on a schedule to verify performance, and MR-conditional equipment engineered so that nothing in the room distorts the field or endangers the patient. MRI Med supplies ACR-standard MRI phantoms and MR-conditional accessories for exactly this control point, alongside phantom and QA specialists such as Sun Nuclear, The Phantom Laboratory, and CIRS. The American College of Radiology (ACR) phantom is a known object; if the scanner reproduces it correctly today and tomorrow, the clinical images can be trusted. Equipment labeled MR-conditional under standards such as ASTM F2503 ensures that accessories brought near the magnet behave predictably. If the phantom check fails, no amount of clever chemistry upstream will save the result.

For a pharma audience running imaging endpoints in trials, this is not a facilities footnote — it is data integrity. Multi-site studies live or die on whether every scanner produces comparable, calibrated output traceable to NIST references, and that comparability is manufactured by disciplined QA, not assumed.

A Closer Look: When Small Inconsistencies Compound

During radioligand development, even small inconsistencies in chelator purity can translate into reduced imaging consistency across multicenter trials — a faint but real drift in signal that undermines quantitative comparison between sites. Layer on scanners that are calibrated to different standards, and a study can lose the statistical power it was designed to have. This is why leading programs increasingly pair GMP-grade DOTA intermediates and validated linker chemistry on the molecule side with rigorous, phantom-based calibration on the machine side. The two disciplines are usually managed by entirely different teams, but they fail together — and, done well, they succeed together.

Where the Two Ends Meet: The Clinic

The chemistry and the machine converge at the point of care, and increasingly that point is the longevity and precision-medicine clinic, where advanced imaging is used not only to diagnose disease but to characterize aging and guide proactive intervention. YoungerMeMD builds programs around advanced diagnostic imaging and longevity diagnostics, part of a wave of practices pushing sophisticated scanning out of the acute-care setting and into continuous, patient-level monitoring.

That shift raises the stakes on both foundations at once. When imaging moves from a one-time diagnostic to a longitudinal tool, reproducibility becomes everything — you cannot track subtle change over years unless both the imaging agent and the scanner behave identically at every visit. The clinic, in other words, is where sloppy chemistry or lax QA finally reveals itself, and where discipline at both ends pays off.

Why Theranostics Are Growing

Several forces are converging at once: an aging population and rising cancer incidence; a wave of FDA approvals validating the radioligand model; reimbursement pathways maturing for nuclear medicine; and isotope supply chains — for lutetium-177, actinium-225, and others — steadily industrializing. Guidelines from bodies such as the NCCN, SNMMI, and EANM increasingly incorporate molecular imaging and radioligand therapy, pulling these approaches from the research frontier into standard practice.

Common Failure Points

• Chelator instability: weak or impure chelators allow radiometals to dissociate, reducing target signal and raising off-target dose.
• Uncalibrated scanners: skipped or inconsistent phantom QA erodes quantitative accuracy across time and sites.
• MR-safety lapses: non-conditional equipment near the magnet distorts fields or endangers patients.
• Cross-site variability: multicenter trials without harmonized standards produce data that cannot be pooled with confidence.

Regulatory and Standards Challenges

Precision imaging sits at the intersection of an unusually dense web of standards. Imaging agents answer to FDA and EMA; scanner performance is benchmarked against ACR accreditation and, ultimately, NIST-traceable references; MR safety follows ASTM F2503 and IEC guidance; and clinical use is shaped by SNMMI, EANM, and NCCN guidelines. Navigating this landscape is itself a competency — and one reason both the chemistry and QA tiers reward specialization over improvisation.

Manufacturing Challenges

Producing theranostic agents at scale means coordinating short-lived isotopes, GMP-grade chelators, and validated conjugation chemistry against the clock — gallium-68 has a roughly 68-minute half-life, while lutetium-177 lasts about 6.6 days, dictating how far a dose can travel before use. On the imaging side, phantoms and MR-conditional hardware must themselves be manufactured to tight, reproducible tolerances, because they are the reference against which everything else is judged.

Industry Trends to Watch

• Theranostics and companion diagnostics expanding beyond oncology
• AI-guided molecular design and AI-assisted image reconstruction
• Personalized and longitudinal imaging in longevity medicine
• New isotopes and targeted alpha therapy (e.g., actinium-225)
• PET/MRI hybrid imaging and quantitative imaging biomarkers
• Standardized, cross-site QA as trials scale globally

Future Outlook

As theranostics, precision medicine, peptide therapeutics, AI-assisted drug discovery, and molecular diagnostics continue converging, the organizations investing in reproducible chemistry, standardized imaging, validated manufacturing, and clinical quality systems will likely shape the next generation of pharmaceutical innovation. Theranostics is usually sold as a story about clever targeting. It is really a story about reproducibility — engineered at two ends that rarely get credit. Upstream, stable, high-purity chelator chemistry determines what an imaging agent can measure. Downstream, phantom-based QA and MR-conditional equipment determine whether the scanner can be believed. The breakthroughs will come from the targeting, but the trust will come from the chemistry and the calibration. Neither is optional.

“As theranostics continue to reshape personalized medicine, the demand for precise, standardized imaging will only grow. The future of diagnostic excellence depends on giving imaging teams the tools they need to deliver consistent, high-quality results that clinicians can trust.” – Rick M., SVP, MRI Med

Frequently Asked Questions

What is DOTA? DOTA is a macrocyclic chelator that forms an exceptionally stable cage around metal ions. It is widely used to attach radiometals or paramagnetic ions to targeting molecules for PET, SPECT, MRI, and radioligand therapy.

Why are chelators important in theranostics? The chelator holds the radioactive or paramagnetic metal in place. If it releases the metal prematurely, the imaging signal weakens and healthy tissue receives unintended dose — so chelator stability directly affects both safety and image quality.

How are MRI phantoms used? A phantom is a standardized object with known properties that is scanned regularly to verify that an MRI is performing correctly. Comparing the scanned result to the known reference reveals drift or error before it affects patient images.

What does MR-conditional mean? MR-conditional describes equipment that is safe to use in the MRI environment under specified conditions, per standards such as ASTM F2503. Using non-conditional items near the magnet can distort images or create safety hazards.

Why does scanner calibration matter for clinical trials? Multicenter trials pool imaging data from many sites. Without harmonized, phantom-verified calibration, differences between scanners can masquerade as real biological change, undermining the study’s conclusions.

Further Reading

Readers interested in the science and systems behind this article may want to explore related topics: theranostics, radiopharmaceuticals, radioligand therapy, PET and PET/CT, PET/MRI, SPECT, MRI quality assurance, DOTA and bifunctional chelators, lutetium-177 and actinium-225, PSMA and DOTATATE imaging, companion diagnostics, imaging biomarkers, and precision and longevity medicine.

The BARBARA platform brings together 180 existing dementia research databases and population health studies into a single system designed to identify suitable participants for clinical trials more efficiently. By consolidating these research resources, pharmaceutical companies can more rapidly recruit appropriate clinical trial participants, while individuals living with dementia, as well as those considered at high risk of developing the condition, can be matched with studies suited to their circumstances.

Commenting on the initiative, James Bethell, chair of the BARBARA project steering committee and former U.K. Minister for Innovation at the Department of Health and Social Care, said, “BARBARA will be the world’s leading dementia data registration system for corporations seeking to test treatments.”

Focus on Accelerating Drug Development and Research Investment

Worldwide, 158 Alzheimer’s treatments are currently under development through 192 clinical trials, while additional drug candidates targeting other forms of dementia are also progressing through research pipelines. Across the pharmaceutical industry, one of the most significant barriers to developing new dementia medicines continues to be the challenge of identifying and enrolling appropriate clinical trial participants. Former Minister Bethell noted that only 173 patients in England participated in late-stage, commercially sponsored Alzheimer’s clinical trials during 2024–2025.

To address this issue, the BARBARA platform has been designed to integrate research data from across the country, enabling pre-screening of potential trial participants and reducing recruitment timelines. The organizations supporting the project believe that combining the platform with early diagnostic technologies based on blood biomarkers (biological indicators that diagnose disease) will make it possible for individuals at high risk of dementia—even before symptoms appear—to participate in research studies. They also expect the system to contribute to the development of precision dementia treatments through genetic analysis.

Beyond supporting dementia drug development, the project’s backers also see the BARBARA platform as an important foundation for attracting global pharmaceutical companies to conduct clinical trials and expand research and development (R&D) activities in Britain. They believe the initiative could help strengthen the country’s life sciences investment environment following the recent conclusion by the National Institute for Health and Care Excellence (NICE) that the Alzheimer’s treatments lecanemab and donanemab were not sufficiently cost-effective in terms of expense.

The amount of funding allocated to develop the platform is expected to be announced later in 2026. Through the initiative, Britain intends to accelerate dementia drug development while positioning itself as a destination for global clinical trials and life sciences investment.

The pharmaceutical landscape is littered with promising drug candidates that falter due to unforeseen toxicity, leading to colossal financial losses and delays. This high attrition rate underscores the critical need for more accurate and efficient methods of drug safety assessment at the earliest stages of discovery. Traditional toxicology, while indispensable, often provides insights too late in the development cycle, after significant resources have already been invested. The imperative is clear: we need to predict potential harm with greater precision and foresight. This is precisely where machine learning in predictive toxicology steps in, offering a sophisticated toolkit to revolutionize toxicity prediction and drive safer, more effective drug development.

The Intricacies of Traditional Toxicity Assessment and the Drive for Innovation

Evaluating the safety profile of a new chemical entity is a multi-faceted challenge. Conventionally, this process involves a tiered approach, starting with preliminary in vitro assays in laboratory settings, progressing to animal studies (in vivo) in the preclinical drug discovery phase, and ultimately culminating in human clinical trials. Each step is designed to meticulously uncover potential adverse effects, ranging from organ damage and carcinogenicity to genotoxicity and developmental issues. However, these methods are not without their limitations. Animal models, while valuable, do not always perfectly translate to human biology, leading to gaps in understanding. Furthermore, they are resource-intensive, time-consuming, and raise significant ethical considerations regarding animal welfare. The sheer volume of new compounds generated by modern synthetic chemistry also overwhelms traditional screening capacities, making it impractical to test every single molecule with the same rigor.

The inherent limitations of these traditional approaches have long fueled the quest for innovative solutions. Researchers and regulatory bodies alike have sought ways to accelerate drug safety assessment while improving its accuracy and reducing its burden. The advent of vast digital datasets – including chemical structures, biological activity profiles, gene expression data, and historical toxicity information – has created fertile ground for computational methodologies. Pharma Advancement highlights that this confluence of data availability and advanced algorithms has paved the way for the transformative application of machine learning in predictive toxicology.

Unveiling the Power of Machine Learning in Toxicology

Machine learning, a branch of artificial intelligence, empowers computers to learn patterns from data without being explicitly programmed. In the realm of toxicology, this means training algorithms on existing datasets of chemical compounds and their known toxicological outcomes. These datasets encompass a wide array of information: from the molecular structures of compounds to their interactions with biological systems, and critically, their observed adverse effects in various models. By analyzing these complex relationships, ML models can learn to predict the toxicity of novel compounds with impressive accuracy. This represents a paradigm shift from reactive testing to proactive safety forecasting.

The foundational principle involves identifying correlations between a compound’s molecular features (e.g., shape, electronic properties, functional groups) and its biological activity or toxicity. This approach is often rooted in Quantitative Structure-Activity Relationship (QSAR) and Quantitative Structure-Property Relationship (QSPR) models, which have existed in various forms for decades. However, modern AI in toxicology supercharges these concepts with advanced algorithms such as support vector machines, random forests, and especially deep learning neural networks. These sophisticated models can uncover highly non-linear and intricate relationships that are beyond the grasp of human intuition or simpler statistical methods. They can process vast, high-dimensional data, learning from thousands of compounds and their associated toxicity profiles across various endpoints, effectively creating a “digital toxicologist.”

Practical Applications and Tangible Benefits in Drug R&D

The integration of machine learning in predictive toxicology brings a multitude of practical applications and tangible benefits to the pharmaceutical R&D pipeline:

• Early Identification of Potential Toxicities: One of the most significant advantages is the ability to flag potential risks much earlier in the drug discovery process. Instead of waiting for laborious in vitro or in vivo tests, ML models can rapidly screen vast libraries of compounds, sifting out those with a high probability of adverse effects. This capability to perform early toxicity prediction saves immense time and resources, allowing researchers to focus their efforts on compounds with more favorable safety profiles. It’s about making informed ‘go/no-go’ decisions well before significant investment.
• Optimizing Compound Design and Selection: Beyond simple screening, ML models can guide medicinal chemists in designing safer molecules. By understanding which structural features correlate with toxicity, chemists can modify candidate compounds to mitigate predicted risks. This iterative design-predict-refine cycle accelerates the identification of lead compounds with improved therapeutic indices. It’s a proactive approach to building safety into the molecule from its inception.
• Reduction in Animal Testing: The ethical and financial pressures to reduce animal testing are immense. Machine learning in predictive toxicology offers a compelling alternative by providing reliable safety forecasting based on existing data. While not entirely replacing animal studies, ML can significantly reduce their number by prioritizing compounds that are more likely to be safe, thus aligning with the 3Rs principles (Replace, Reduce, Refine) in animal research.
• Enhanced Efficiency in Preclinical Drug Discovery: By streamlining the selection of viable drug candidates and reducing the number of compounds that fail due to toxicity, ML significantly accelerates the overall preclinical drug discovery timeline. This enhanced efficiency means that promising new drugs can potentially reach patients faster, addressing unmet medical needs with greater urgency.
• Predicting Specific Toxicological Endpoints: Advanced ML models are not limited to general toxicity prediction. They can be trained to predict specific adverse events, such as hepatotoxicity (liver damage), cardiotoxicity (heart damage), nephrotoxicity (kidney damage), or genotoxicity (DNA damage). This targeted toxicity prediction allows researchers to anticipate and address organ-specific risks with greater precision.

Navigating the Challenges and Future Outlook

While the promise of machine learning in predictive toxicology is immense, its implementation is not without challenges. One significant hurdle is the quality and quantity of data. ML models are only as good as the data they are trained on. High-quality, standardized, and diverse datasets are crucial for building robust and generalizable models. Another challenge lies in model interpretability. Some advanced deep learning models can act as “black boxes,” making it difficult to understand why a particular prediction was made. For regulatory approval and scientific validation, understanding the rationale behind a prediction is often as important as the prediction itself. Efforts are continuously underway to develop more interpretable AI models (e.g., explainable AI or XAI). Furthermore, integrating these novel computational tools seamlessly into existing pharmaceutical R&D workflows requires significant investment in infrastructure, expertise, and a cultural shift within organizations.

Despite these challenges, the trajectory for machine learning in predictive toxicology is undeniably upward. We are witnessing continuous advancements in algorithm design, the development of richer and more diverse datasets, and increasing collaboration between AI experts and toxicologists. The future will likely see even more sophisticated models capable of predicting complex, multi-organ toxicities, integrating in silico predictions with in vitro high-throughput screening data, and even contributing to personalized medicine by predicting individual patient responses to drugs based on their genetic makeup. Pharma Advancement notes that the evolution of AI in toxicology points towards a future where drug safety assessment is not just a gatekeeper, but an intelligent guide, shaping the very design of our medicines.

Patients with metastatic pancreatic cancer whose disease continues to progress after earlier treatment currently face very limited therapeutic options and generally have a poor prognosis, with a life expectancy of around six months. This situation represents a significant unmet medical need, making the development of new treatment options particularly important.

In recognition of its potential to address this challenge, daraxonrasib has been identified as a high-priority medicine under EMA’s Cancer Medicines Pathfinder project. As a result, the medicine qualified for an expedited assessment of its eligibility for a centralised marketing authorisation application. To further accelerate the regulatory process, the CHMP agreed to examine quality, nonclinical, and clinical data in a phased approach as they are submitted, ahead of the complete marketing authorisation application submission. This phased assessment is expected to support a more efficient review while ensuring that every aspect of the medicine continues to meet established standards for quality, safety, and efficacy.

Phased Review Expected to Support Faster Regulatory Evaluation

According to EMA, the review of daraxonrasib will also serve as an example of how certain provisions within the reformed EU pharmaceutical legislation could strengthen the future use of phased reviews. The updated legislative framework envisions phased reviews as a practical tool for creating a more agile and streamlined evaluation process for medicines with the potential to address major public health needs.

Although EMA noted that the total review timeline for daraxonrasib cannot yet be predicted, the agency expects the process to be shorter than a conventional evaluation because part of the scientific assessment will already have been completed before the full marketing authorisation application is filed.

Looking ahead, EMA, in agreement with the CHMP, plans to consider additional medicines under development for phased review whenever this regulatory pathway is considered feasible and likely to accelerate assessment. Decisions will continue to be made on a case-by-case basis, taking into account whether a medicine is expected to address an unmet medical need and whether it represents a significant public health interest, particularly in terms of therapeutic innovation.

Integration of the NMTi Payload Platform

The acquisition centers on the development of antibody-drug conjugates that utilize a specialized NMTi payload platform. These next-generation payloads employ N-myristoyltransferase inhibitors to target malignant cells, offering a different approach compared to traditional topoisomerase 1 inhibitors. This technology is designed to address the limitations of current therapies and provide new options for patients facing treatment resistance.

Clinical Applications in Solid Tumor Therapy

Novartis will integrate a pipeline featuring two lead candidates. These candidates are directed at B7 homologue 3 (B7-H3) and human epidermal growth factor receptor 2 (HER2). This indicates a broad potential for application across various solid tumor types.

Fiona Marshall, the president of biomedical research at Novartis, stated, “ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients.”

“This proposed acquisition reflects our strategy to scale innovative platforms, as we have with radioligand therapies, to deliver more durable, transformative treatments for patients,” she added.

Preclinical data suggests that these NMTi payloads exhibit significant activity in solid tumors, including those that have proven resistant to existing therapeutic classes. By overtakingMyricx Bio, the organization aims to establish these inhibitors as a validated class of payloads for a variety of clinical targets.

Additional Regulatory Milestones

In a separate development, the European Commission has granted approval for the Novartis’ Itvisma. This treatment is indicated for children aged two and older, as well as teenagers and adults, who have 5q spinal muscular atrophy  with a bi-allelic mutation in the survival motor neuron 1 gene.